Selective androgen receptor modulator has anti-tumor effects in ER-positive breast ca
 

A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor has anti-tumour effects in estrogen receptor positive breast cancer patients.

More...